Triflusal Posttreatment Inhibits Glial Nuclear Factor-κB, Downregulates the Glial Response, and Is Neuroprotective in an Excitotoxic Injury Model in Postnatal Brain
- 1 October 2001
- journal article
- other
- Published by Wolters Kluwer Health in Stroke
- Vol. 32 (10), 2394-2402
- https://doi.org/10.1161/hs1001.097243
Abstract
Background and Purpose — Nuclear factor-κB (NF-κB) and the signal transducer and activator of transcription 3 (STAT3) are important transcription factors regulating inflammatory mechanisms and the glial response to neural injury, determining lesion outcome. In this study we evaluate the ability of triflusal (2-acetoxy-4-trifluoromethylbenzoic acid), an antiplatelet agent inhibitor of NF-κB activation, to improve lesion outcome after excitotoxic damage to the immature brain. Methods — Postnatal day 9 rats received an intracortical injection of the excitotoxin N -methyl- d -aspartate (NMDA) and oral administration of triflusal (30 mg/kg) either as 3 doses before NMDA injection (pretreatment) or as a single dose 8 hours after NMDA injection (posttreatment). After survival times of 10 and 24 hours, brains were processed for toluidine blue staining, tomato lectin histochemistry, and glial fibrillary acidic protein, NF-κB, and STAT3 immunocytochemistry. Results — NMDA-lesioned animals that were not treated with triflusal showed activation of NF-κB in neuronal cells at first and in glial cells subsequently. Animals that received pretreatment with triflusal showed a strong downregulation of neuronal and glial NF-κB but a similar development of the glial response and an equivalent lesion volume compared with nontreated animals. In contrast, animals receiving triflusal posttreatment showed increased early neuronal NF-κB but a reduction in the subsequent glial NF-κB, accompanied by important downregulation of the microglial and astroglial response and a drastic reduction in the lesion size. STAT3 activation was not affected by triflusal treatment. Conclusions — Triflusal posttreatment diminishes glial NF-κB, downregulates the glial response, and improves the lesion outcome, suggesting a neuroprotective role of this compound against excitotoxic injury in the immature brain.Keywords
This publication has 57 references indexed in Scilit:
- Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-κB activationNeuroReport, 2000
- Stat3 and NFκB glial expression after excitotoxic damage to the postnatal brainNeuroReport, 1998
- Pro-inflammatory signaling: Last pieces in the NF-κB puzzle?Current Biology, 1998
- TriflusalDrugs, 1998
- Expression and Regulation of Cyclooxygenase‐2 in Rat MicrogliaEuropean Journal of Biochemistry, 1997
- Induction of Stat3, a Signal Transducer and Transcription Factor, in Reactive Microglia following Transient Focal Cerebral IschaemiaEuropean Journal of Neuroscience, 1996
- Enhancement of immunoreactivity for NF-κB in human cerebral infarctionsBrain Research, 1996
- Increased cortical nuclear factor-κB (NF-κB) DNA binding activity after traumatic brain injury in ratsNeuroscience Letters, 1995
- TRANSCRIPTIONAL RESPONSES TO POLYPEPTIDE LIGANDS: The JAK-STAT PathwayAnnual Review of Biochemistry, 1995
- Demonstration of poly-N-acetyl lactosamine residues in ameboid and ramified microglial cells in rat brain by tomato lectin binding.Journal of Histochemistry & Cytochemistry, 1994